BRPI0413374A - composições para liberação de base fraca por um perìodo estendido de tempo - Google Patents

composições para liberação de base fraca por um perìodo estendido de tempo

Info

Publication number
BRPI0413374A
BRPI0413374A BRPI0413374-9A BRPI0413374A BRPI0413374A BR PI0413374 A BRPI0413374 A BR PI0413374A BR PI0413374 A BRPI0413374 A BR PI0413374A BR PI0413374 A BRPI0413374 A BR PI0413374A
Authority
BR
Brazil
Prior art keywords
extended period
dosage form
weak base
time
release compositions
Prior art date
Application number
BRPI0413374-9A
Other languages
English (en)
Inventor
John Francis Hoke
Luigi Martini
Vincenzo Re
Mark Edward Sale
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0413374(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of BRPI0413374A publication Critical patent/BRPI0413374A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçõES PARA LIBERAçãO DE BASE FRACA POR UM PERìODO ESTENDIDO DE TEMPO". Uma forma de dosagem oral compreendendo uma primeira composição e uma segunda composição, cada composição compreendendo uma base fraca farmacêuticamente aceitável, especialmente o Composto A ou um sal ou solvato farmacêuticamente aceitável do mesmo, ('o medicamento') e um veículo farmacêuticamente aceitável então, onde a primeira e segunda composições são planejadas para liberar medicamentos a diferentes taxas de liberação em administração de forma que a taxa de liberação do medicamento a partir da forma de dosagem é substancialmente independente de pH; um processo para preparar tal forma de dosagem e o uso de tal forma de dosagem na medicina.
BRPI0413374-9A 2003-08-07 2004-08-06 composições para liberação de base fraca por um perìodo estendido de tempo BRPI0413374A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49338803P 2003-08-07 2003-08-07
PCT/EP2004/008843 WO2005013935A2 (en) 2003-08-07 2004-08-06 Composition for releasing a weak base for an extended period of time

Publications (1)

Publication Number Publication Date
BRPI0413374A true BRPI0413374A (pt) 2006-10-17

Family

ID=34135242

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413374-9A BRPI0413374A (pt) 2003-08-07 2004-08-06 composições para liberação de base fraca por um perìodo estendido de tempo

Country Status (25)

Country Link
US (1) US20070134326A1 (pt)
EP (1) EP1660049A2 (pt)
JP (1) JP2007501773A (pt)
KR (1) KR20060113650A (pt)
CN (2) CN101239047A (pt)
AP (1) AP2006003488A0 (pt)
AR (1) AR045330A1 (pt)
AU (1) AU2004262926B2 (pt)
BR (1) BRPI0413374A (pt)
CA (1) CA2534546A1 (pt)
EA (2) EA011508B1 (pt)
EC (1) ECSP066318A (pt)
IL (1) IL173176A0 (pt)
IS (1) IS8336A (pt)
MA (1) MA27980A1 (pt)
MX (1) MXPA06001407A (pt)
NO (1) NO20061018L (pt)
NZ (1) NZ544696A (pt)
OA (1) OA13230A (pt)
PE (1) PE20050335A1 (pt)
SG (1) SG145717A1 (pt)
TW (1) TW200517127A (pt)
UY (1) UY28457A1 (pt)
WO (1) WO2005013935A2 (pt)
ZA (1) ZA200600521B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
GB0502479D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
MX381895B (es) 2009-02-13 2025-03-13 Romark Laboratories Lc Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.
CA2787247A1 (en) 2010-01-20 2011-07-28 Glaxo Group Limited Novel composition
CN103948557A (zh) * 2014-04-08 2014-07-30 闻晓光 一种新型控释片

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
AU5745601A (en) * 2000-05-01 2001-11-12 Aeropharm Technology Inc A core formulation
GB0117618D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
MY139719A (en) * 2002-02-12 2009-10-30 Glaxo Group Ltd Oral dosage form for controlled drug release

Also Published As

Publication number Publication date
AR045330A1 (es) 2005-10-26
US20070134326A1 (en) 2007-06-14
ZA200600521B (en) 2007-01-31
SG145717A1 (en) 2008-09-29
CN101239047A (zh) 2008-08-13
JP2007501773A (ja) 2007-02-01
AU2004262926B2 (en) 2009-11-19
AP2006003488A0 (en) 2006-02-28
UY28457A1 (es) 2005-03-31
IS8336A (is) 2006-03-02
KR20060113650A (ko) 2006-11-02
EA200701409A1 (ru) 2007-10-26
CN1832729A (zh) 2006-09-13
OA13230A (en) 2006-12-13
MA27980A1 (fr) 2006-07-03
WO2005013935A2 (en) 2005-02-17
ECSP066318A (es) 2006-07-28
TW200517127A (en) 2005-06-01
EA200600377A1 (ru) 2006-08-25
PE20050335A1 (es) 2005-06-01
MXPA06001407A (es) 2006-05-15
EP1660049A2 (en) 2006-05-31
AU2004262926A1 (en) 2005-02-17
WO2005013935A3 (en) 2005-07-14
EA011508B1 (ru) 2009-04-28
NO20061018L (no) 2006-03-01
CA2534546A1 (en) 2005-02-17
NZ544696A (en) 2009-03-31
IL173176A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
TW200500098A (en) Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
BR0015188A (pt) Composições farmacêuticas
BRPI0409962A (pt) co-formulação particulada de uma substáncia ativa e um excipiente, composição farmacêutica ou nutricêutrica, produto farmacêutico ou nutricêutico, método para preparar uma co-formulação particulada de uma substáncia ativa e um excipiente, e, uso de uma substáncia ativa e um excipiente
UY27533A1 (es) Composiciones farmacéuticas que contienen oxibutinina
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
BR0007974A (pt) Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo
BR0211198A (pt) Composições farmacêuticas e seu uso
AR033688A1 (es) Composicion parenteral reconstituible
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
DE602005025755D1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
ATE292453T1 (de) Antivirale arznei
ATE466008T1 (de) P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
AP2003002763A0 (en) Controlled release formulations for oral administration
MXPA06007510A (es) Composiciones de farmaco y formas de dosis novedosas de topiramato.
SG145717A1 (en) Composition for releasing a weak base for an extended period of time
BRPI0606768A2 (pt) forma de dosagem oral compreendendo rosiglitazona
DK1152763T3 (da) Anvendelse af desozypeganin til behandling af stofafhængighed
BR0307319A (pt) Forma de dosagem oral para liberação controlada de droga
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
ATE302010T1 (de) Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]